Related references
Note: Only part of the references are listed.Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma
Eric Salazar et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
The convalescent sera option for containing COVID-19
Arturo Casadevall et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho
Andrew Bryan et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto et al.
NATURE (2020)
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Eric Salazar et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato et al.
BLOOD (2020)
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020
Heli Harvala et al.
EUROSURVEILLANCE (2020)
Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment
Jing Sun et al.
CELL (2020)
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial
Ling Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019
Steven B. Bradfute et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients
Michael J. Joyner et al.
MAYO CLINIC PROCEEDINGS (2020)
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Davide F. Robbiani et al.
NATURE (2020)
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Thomas F. Rogers et al.
SCIENCE (2020)
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Philip J. M. Brouwer et al.
SCIENCE (2020)
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Alina Baum et al.
SCIENCE (2020)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Anup Agarwal et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies
Il-Kang Na et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Yaseen M. Arabi et al.
EMERGING INFECTIOUS DISEASES (2016)
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses
Ken M. Kunisaki et al.
LANCET INFECTIOUS DISEASES (2009)
Use of convalescent plasma therapy in SARS patients in Hong Kong
Y Cheng et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Share Paper
